Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAfter two weeks on semaglutide, most people notice early appetite changes rather than dramatic weight loss. The body is still adjusting to the starting dose, and the first measurable changes tend to be in hunger patterns and how much feels like enough at mealtimes. These early signals matter, but they are not the full picture. Semaglutide is a prescription-only medicine; a GPhC-registered prescriber assesses your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture this: you gave yourself your first weekly injection a fortnight ago. The pen went back in the fridge, and you've been watching for something to happen. If what you've noticed is mainly a quieter appetite rather than a lower number on the scales, you're in exactly the right place for week two.
Semaglutide activates GLP-1 receptors in the gut and brain, slowing the rate at which your stomach empties and turning down the hormonal signals that tell you to eat. Those changes begin from dose one, but they are dose-dependent. At 0.25 mg (the standard opening dose) the effect is deliberately gentle. Your prescriber starts here to reduce the likelihood of nausea, not because the medicine isn't working.
What most people describe at two weeks is a shift in the experience of eating: portions that used to feel normal now feel like too much, and the urge to snack between meals loosens a little. Some notice that food thoughts occupy less mental space. These are early signs the medicine is doing something real. You can read more about the broader trajectory in our week-by-week semaglutide results guide, which covers how that picture develops over the following months.
A question our prescribers hear most weeks is some version of: "I've been on it two weeks and I've only lost a pound or two) is it even working?" The answer, almost always, is yes.
The landmark STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4 mg maintenance dose. That figure, read carefully, tells you something important: almost all of the clinically significant loss came after the titration period was complete. The early weeks are the foundation, not the result.
At two weeks on the starter dose, a realistic loss of 0.5–2 kg reflects water and glycogen shifts as much as fat loss. That's normal physiology, not underperformance. The dose will be reviewed by your prescriber before increasing; if you want a clearer sense of what to expect right now, our page on semaglutide 1 week results explains what typically happens in those very first days and how that compares to where you are now. For a sense of how results tend to build from here, our page on semaglutide at four weeks covers what changes once the first titration lands.
Cost and access questions sometimes arise at this stage too. If you're comparing your options, our Wegovy price guide sets out what a legitimate private prescription typically includes.
Nausea is the side effect people talk about most, and it peaks early. For many people, it's worst in the first day or two after each injection, then fades before the next dose is due. Eating smaller portions and avoiding very fatty or rich meals helps considerably. Other common experiences at this stage include mild indigestion, softer stools or constipation, and occasional headaches, the NHS semaglutide medicines page lists these and gives plain-English guidance on managing them.
Most GI symptoms at two weeks are the body's response to a medicine that genuinely slows gastric emptying. They are uncomfortable but not dangerous in their typical form. They also tend to settle as the weeks pass.
Two symptoms warrant prompt medical attention at any stage, not just now. Severe stomach pain that extends to the back, particularly if accompanied by vomiting, should be assessed urgently, this is the warning sign for pancreatitis, a rare but serious side effect that the MHRA highlighted in a 2026 safety communication. Signs of significant dehydration from persistent vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down) also need same-day medical input. When in doubt, contact your GP or call 111.
If you are prescribed semaglutide through nume, our prescribers are available seven days a week for aftercare questions, including the ones that feel too small to raise. Nothing is too small at week two.
The two-week point is one of the trickier moments in treatment. Expectations, often shaped by social media accounts of dramatic early drops, can clash with a much quieter real-world experience. Understanding that gap matters.
Semaglutide works cumulatively. The appetite suppression deepens as the dose increases; the metabolic adaptations build over months; the habit changes that often accompany reduced hunger compound over time. People who see modest semaglutide week 2 results and stay the course reliably see more movement at eight weeks and beyond, our guide to semaglutide results at eight weeks gives a clearer picture of what that progression typically looks like.
If you are curious about how semaglutide compares to other licensed treatments, or whether Wegovy is the right starting point for your situation, our Wegovy overview covers the full licensed context. And if you haven't yet had a clinical assessment, the straightforward place to start is a free consultation with our prescribers.
Two weeks is week two of a much longer story. The early data points are worth tracking, but they rarely write the ending.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.